Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the ...
We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against Jim Cramer’s other must-watch ...
Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results